Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Delivery Systems | 10 | 2018 | 252 | 1.330 |
Why?
|
| Nanoparticles | 7 | 2015 | 104 | 0.800 |
Why?
|
| Antiparkinson Agents | 3 | 2018 | 15 | 0.580 |
Why?
|
| Tissue Engineering | 3 | 2015 | 52 | 0.570 |
Why?
|
| Tissue Scaffolds | 3 | 2015 | 45 | 0.500 |
Why?
|
| Polymers | 5 | 2016 | 133 | 0.460 |
Why?
|
| Parkinson Disease | 3 | 2010 | 19 | 0.450 |
Why?
|
| Brain Injuries | 1 | 2013 | 3 | 0.440 |
Why?
|
| Levodopa | 2 | 2011 | 20 | 0.440 |
Why?
|
| Neurodegenerative Diseases | 2 | 2009 | 19 | 0.410 |
Why?
|
| Drug Compounding | 2 | 2010 | 22 | 0.360 |
Why?
|
| Peptides | 1 | 2011 | 40 | 0.360 |
Why?
|
| Nanostructures | 1 | 2011 | 40 | 0.350 |
Why?
|
| Nanotechnology | 2 | 2011 | 28 | 0.350 |
Why?
|
| Alzheimer Disease | 4 | 2012 | 30 | 0.290 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 14 | 0.290 |
Why?
|
| Central Nervous System Agents | 2 | 2016 | 9 | 0.250 |
Why?
|
| Nerve Regeneration | 3 | 2015 | 22 | 0.250 |
Why?
|
| Methacrylates | 2 | 2018 | 14 | 0.250 |
Why?
|
| Animals | 10 | 2018 | 1081 | 0.230 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 18 | 0.230 |
Why?
|
| Technology, Pharmaceutical | 2 | 2015 | 35 | 0.200 |
Why?
|
| Drug Carriers | 2 | 2015 | 93 | 0.200 |
Why?
|
| Humans | 13 | 2016 | 14537 | 0.190 |
Why?
|
| Drug Implants | 2 | 2016 | 24 | 0.150 |
Why?
|
| Pentetic Acid | 1 | 2018 | 4 | 0.150 |
Why?
|
| Amantadine | 1 | 2018 | 6 | 0.150 |
Why?
|
| Nanospheres | 1 | 2018 | 13 | 0.150 |
Why?
|
| Amyloid beta-Peptides | 3 | 2012 | 22 | 0.140 |
Why?
|
| Blood-Brain Barrier | 3 | 2016 | 24 | 0.140 |
Why?
|
| Hydrogels | 2 | 2015 | 42 | 0.140 |
Why?
|
| Rats | 5 | 2016 | 130 | 0.140 |
Why?
|
| Nanocomposites | 1 | 2016 | 6 | 0.130 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 7 | 0.130 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 17 | 0.130 |
Why?
|
| Liposomes | 2 | 2013 | 33 | 0.130 |
Why?
|
| AIDS Dementia Complex | 1 | 2015 | 29 | 0.130 |
Why?
|
| Chitosan | 2 | 2012 | 46 | 0.120 |
Why?
|
| Nanomedicine | 1 | 2015 | 24 | 0.120 |
Why?
|
| Hospital Rapid Response Team | 1 | 2013 | 1 | 0.110 |
Why?
|
| Trauma Severity Indices | 1 | 2013 | 4 | 0.110 |
Why?
|
| Accidents, Traffic | 1 | 2013 | 5 | 0.110 |
Why?
|
| Particle Size | 4 | 2016 | 73 | 0.110 |
Why?
|
| Trauma Centers | 1 | 2013 | 4 | 0.110 |
Why?
|
| Biocompatible Materials | 2 | 2015 | 60 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 68 | 0.110 |
Why?
|
| Nootropic Agents | 1 | 2013 | 4 | 0.110 |
Why?
|
| Galantamine | 1 | 2013 | 6 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2013 | 16 | 0.110 |
Why?
|
| Computer Simulation | 2 | 2011 | 56 | 0.110 |
Why?
|
| Acrylic Resins | 1 | 2012 | 17 | 0.100 |
Why?
|
| Chelating Agents | 1 | 2012 | 11 | 0.100 |
Why?
|
| Incidence | 1 | 2013 | 685 | 0.090 |
Why?
|
| Peptidomimetics | 1 | 2011 | 4 | 0.090 |
Why?
|
| Prostheses and Implants | 1 | 2011 | 5 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 12 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 18 | 0.090 |
Why?
|
| Patents as Topic | 1 | 2011 | 18 | 0.090 |
Why?
|
| Curcumin | 1 | 2011 | 13 | 0.090 |
Why?
|
| Nicotine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Computational Biology | 1 | 2011 | 44 | 0.090 |
Why?
|
| Ligands | 3 | 2018 | 33 | 0.090 |
Why?
|
| Models, Neurological | 1 | 2010 | 4 | 0.090 |
Why?
|
| Dosage Forms | 1 | 2010 | 8 | 0.090 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 8 | 0.090 |
Why?
|
| PC12 Cells | 3 | 2016 | 16 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2009 | 3 | 0.080 |
Why?
|
| Dopamine | 1 | 2009 | 7 | 0.080 |
Why?
|
| Biometry | 1 | 2009 | 5 | 0.080 |
Why?
|
| Models, Biological | 1 | 2010 | 77 | 0.080 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 6 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2015 | 76 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2015 | 34 | 0.080 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 3 | 2015 | 44 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2013 | 18 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2012 | 84 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2010 | 889 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 71 | 0.060 |
Why?
|
| Solubility | 2 | 2015 | 51 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2015 | 63 | 0.050 |
Why?
|
| Surface Properties | 2 | 2013 | 46 | 0.050 |
Why?
|
| Molecular Conformation | 2 | 2012 | 14 | 0.050 |
Why?
|
| Neurons | 2 | 2012 | 23 | 0.050 |
Why?
|
| Dopamine Agents | 2 | 2011 | 11 | 0.040 |
Why?
|
| Cross-Linking Reagents | 2 | 2011 | 33 | 0.040 |
Why?
|
| South Africa | 1 | 2013 | 7596 | 0.040 |
Why?
|
| Polyesters | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2018 | 79 | 0.040 |
Why?
|
| Mice | 1 | 2018 | 135 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2016 | 11 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 7 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 10 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 31 | 0.030 |
Why?
|
| Zidovudine | 1 | 2015 | 59 | 0.030 |
Why?
|
| Brain | 1 | 2015 | 53 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2015 | 4 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2015 | 5 | 0.030 |
Why?
|
| Axons | 1 | 2015 | 7 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 43 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2013 | 4 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2013 | 9 | 0.030 |
Why?
|
| Potassium Compounds | 1 | 2012 | 4 | 0.030 |
Why?
|
| Polymerization | 1 | 2012 | 4 | 0.030 |
Why?
|
| Sulfates | 1 | 2012 | 7 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2012 | 13 | 0.030 |
Why?
|
| Viscosity | 1 | 2012 | 16 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2012 | 19 | 0.030 |
Why?
|
| Lipids | 1 | 2013 | 81 | 0.030 |
Why?
|
| Zinc | 1 | 2012 | 10 | 0.030 |
Why?
|
| Copper | 1 | 2012 | 15 | 0.030 |
Why?
|
| Lecithins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Polyphosphates | 1 | 2011 | 10 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 63 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 37 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 127 | 0.020 |
Why?
|
| Male | 2 | 2015 | 6754 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 106 | 0.020 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2009 | 20 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 2009 | 19 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2009 | 19 | 0.020 |
Why?
|
| Cellulose | 1 | 2009 | 21 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 65 | 0.020 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2009 | 5 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2009 | 6 | 0.020 |
Why?
|
| tau Proteins | 1 | 2009 | 7 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2009 | 13 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 10 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 18 | 0.020 |
Why?
|
| Alginates | 1 | 2009 | 34 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 55 | 0.020 |
Why?
|
| Huntington Disease | 1 | 2009 | 22 | 0.020 |
Why?
|